Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William J. Leiby who wrote (569)	2/18/1998 1:23:00 PM
From: Wesley0428	Read Replies (2) of 849

Quick notes from conference call: Appears NMP-22 sales have bottomed. Expect revenue growth from here. Journal of Urology piece will help. New distributor should be finalized (and named) by end of Q1 (delay is to allow management of transition for existing customers). Collecting clinical data to apply to FDA for approval as a "screening" diagnostic, hope to submit to FDA by end of year. NuMa colerectal working its way through FDA 510k process. They expect it to get approved in the first half of 1998. That's later than I'd hoped. Cervical- Bayer evaluating the data. Have until July to decide. Matritech looking to partner with someone on manual versions of this test, which would initially be targeted towaed resolving "tough" cases. Doesn't sound like any silver bullet. Breast - prototype complete. Expect to conduct pre-clinical trials this year. Prostate- Looking at developing a blood based version which would overcome some of the weaknesses of PSA General - looking to establish some type of partnership with multiple "automated system" manufacturers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next